@Article{Oncologie.2021.015503,
AUTHOR = {Peng Wang, Haiyang Zhang, Zilian Cui, Xunbo Jin, Dong Zhang},
TITLE = {Mir-612 Inhibits Proliferation and Invasion of Urothelial Carcinoma of Bladder Cells through Activating Hippo Pathway via Targeting PMEPA1},
JOURNAL = {Oncologie},
VOLUME = {23},
YEAR = {2021},
NUMBER = {2},
PAGES = {259--268},
URL = {http://www.techscience.com/oncologie/v23n2/42962},
ISSN = {1765-2839},
ABSTRACT = {Urothelial carcinoma of bladder (UCB) is a common urological malignancy in the world, but its progression
mechanism remains unclear. MiR-612 was found as an anti-tumor factor in multiple types of cancer, while
few studies have revealed its functions in UCB cells. Based on this, UCB cells such as HTB-9 and HTB-4, and
normal urothelial of bladder cells such as SV-Huc1, were used as subjects in this study. Western blot, qRTPCR, CCK-8 assay and transwell assay were used to assess functions of miR-612 in UCB cells. The database,
miRWalk, was used to search for potential targets of miR-612, and dual-luciferase reporter assay was used to
verify the accuracy of the forecasting results. Besides, PMEPA1 overexpressed vector and miR-612 mimics were
co-transfected into HTB-4 to observe the regulation mechanism of miR-612. It was found that miR-612 was
significantly downregulated in HTB-9 and HTB-4 cells rather than in SV-Huc1 cells, and overexpressed
miR-612 reduced the proliferation and invasion of HTB-4 cells. The expression level of YAP1 was negatively related
with miR-612 while LATS1 was positively related with miR-612. Besides, the results of miRWalk and dual-luciferase
reporter assay indicated that PMEPA1 was a target of miR-612, and overexpression of PMEPA1 could reverse the
effects of miR-612 on UCB including weakened proliferation and invasion abilities, low expression level of YAP1 and
high expression level of LATS1. Therefore, this study suggests that miR-612 inhibits the proliferation and invasion of
urothelial carcinoma of bladder cells through activating Hippo pathway via targeting PMEPA1.},
DOI = {10.32604/Oncologie.2021.015503}
}